NanoViricides, Inc. Files 8-K on Officer/Director Changes

TL;DR

NanoViricides leadership shakeup, new directors/officers appointed.

AI Summary

On September 25, 2025, NanoViricides, Inc. filed an 8-K report. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.

Why It Matters

This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in key personnel and board composition can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• NanoViricides, Inc. (company) — Registrant
• September 25, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $400,000 — 0, 2026 at a base annual base salary of $400,000. Dr. Diwan shall be entitled to partici
• $2 m — surance policy for Dr. Diwan, valued at $2 million, of which $1 million shall be ass
• $1 million — . Diwan, valued at $2 million, of which $1 million shall be assigned to the Registrant and
• $0.00001 — t's Series A Preferred Stock, par value $0.00001 per share to Dr. Diwan. Dr. Diwan's rig
• $9,000 — e (3) years with a base compensation of $9,000 per month and 129 shares of Series A pr
• $10,800 — her cash compensation was increased to $10,800 per month. The Vyas Extension is for a
• $2,500 — e that she subscribes to, not to exceed $2,500 per month. A copy of the Vyas Extension
• $2,000,000 — to the Company in the maximum amount of $2,000,000. All amounts outstanding under the Line
• $2 million — eased the available line of credit from $2 million to $3 million, and extended the maturit
• $3 m — lable line of credit from $2 million to $3 million, and extended the maturity of the

Filing Documents

• tm2527703d1_8k.htm (8-K) — 31KB
• tm2527703d1_ex10-1.htm (EX-10.1) — 16KB
• tm2527703d1_ex10-2.htm (EX-10.2) — 6KB
• tm2527703d1_ex10-3.htm (EX-10.3) — 56KB
• tm2527703d1_ex10-4.htm (EX-10.4) — 29KB
• tm2527703d1_ex10-5.htm (EX-10.5) — 57KB
• 0001104659-25-095676.txt ( ) — 400KB
• nnvc-20250925.xsd (EX-101.SCH) — 3KB
• nnvc-20250925_lab.xml (EX-101.LAB) — 33KB
• nnvc-20250925_pre.xml (EX-101.PRE) — 22KB
• tm2527703d1_8k_htm.xml (XML) — 3KB

02. Compensatory Arrangements of Certain Officers

Item 5.02. Compensatory Arrangements of Certain Officers. Extension Employment Agreement - Anil Diwan On September 25, 2025, NanoViricides, Inc. (the "Registrant") entered into an Extension Agreement effective July 1, 2025 (the "Diwan Extension") of the Employment Agreement with Dr. Anil R. Diwan entered into on July 1, 2018 (the "Diwan Employment Agreement") to continue to serve as the President of the Registrant, effective July 1, 2025. The Extension provides that Dr. Diwan will continue to serve as the Registrant's President until June 30, 2026 at a base annual base salary of $400,000. Dr. Diwan shall be entitled to participate in all fringe benefits the Registrant provides for its employees generally and such other benefits as the Registrant provides for its senior executives. In addition, the Registrant shall maintain a Term Life Insurance policy for Dr. Diwan, valued at $2 million, of which $1 million shall be assigned to the Registrant and the remaining balance to Dr. Diwan's estate. In addition, as an incentive towards the ultimate success of the Registrant, and to provide leadership authority to Dr. Diwan, the Registrant granted 10,204 shares of the Registrant's Series A Preferred Stock, par value $0.00001 per share to Dr. Diwan. Dr. Diwan's rights in the shares shall vest in equal, quarterly installments commencing on September 30, 2025 and fully vest on June 30, 2026. Dr. Diwan will be eligible to receive severance if he is terminated by the Registrant other than for cause in which event the Registrant shall pay to Dr. Diwan an amount equal to six (6) month's salary as severance compensation (without regard to compensation or benefits Dr. Diwan receives from any other source). Dr. Diwan shall be eligible for all benefits during this six (6) month period including bonuses, vesting of previously awarded stock options, health care insurance and other fringe benefits that have been ongoing. The Registrant may elect to pay such severance compensation in

SIGNATURES

SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. NANOVIRICIDES, INC. Date: October 1, 2025 By: /s/ Anil Diwan Name: Anil Diwan Title: President, Chairman

View Full Filing

View this 8-K filing on SEC EDGAR